FGF-3; FGF-4; MCF-7; breast cancer cells; tumorigenicity; VEGF
Abstract :
[en] The transforming properties of fibroblast growth factor 3 (FGF-3) were investigated in MCF7 breast cancer cells and compared to those of FGF-4, a known oncogenic product. The short form of fgf-3 and the fgf-4 sequences were each introduced with retroviral vectors and the proteins were only detected in the cytoplasm of the infected cells, as expected. In vitro, cells producing FGF-3 (MCF7.fgf-3) and FGF-4 (MCF7.fgf-4) displayed an amount of estrogen receptors decreased to around 45% of the control value. However, MCF7.fgf-3 cell proliferation remained responsive to estradiol supply. The sensitivity of the MCF7.fgf-4 cells, if existant, was masked by the important mitogenic action exerted by FGF-4. In vivo, the MCF7.fgf-3 and MCF7.fgf-4 cells gave rise to tumors under conditions in which the control cells were not tumorigenic. Supplementing the mice with estrogen had the paradoxical effect of totally suppressing the start of the FGF-3 as well as the FGF-4 tumors. Tumorigenicity in the presence of matrigel was similar for MCF7.fgf-3 and control cells and was increased by estrogen supplementation. Once started, the MCF7.fgf-4 tumors grew with a characteristic high rate. Remarkably, FGF-4 but not FGF-3, stimulated the secretion of vascular endothelial growth factor (VEGF165) without altering the steady-state level of its mRNA, suggesting a possible regulation of VEGF synthesis at the translational level in MCF7 cells. The increased VEGF secretion is probably involved in the more aggressive phenotype of the MCF7.fgf-4 cells while a decreased dependence upon micro-environmental factors might be part of the increased tumorigenic potential of the MCF7.fgf-3 cells.
Deroanne, Christophe ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Protéines et glycoprot. de matr.extracell. et membran.basal.
Noël, Agnès ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Biologie cellulaire et moléculaire appliquée à l'homme
Collette, Julien ; Centre Hospitalier Universitaire de Liège - CHU > Chimie médicale
Nusgens, Betty ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Protéines et glycoprot. de matr.extracell. et membran.basal.
Foidart, Jean-Michel ; Université de Liège - ULiège > Département des sciences cliniques > Gynécologie - Obstétrique
Calberg-Bacq, C. M.
Language :
English
Title :
Progression in MCF-7 Breast Cancer Cell Tumorigenicity: Compared Effect of FGF-3 and FGF-4.
1. Koga C, Adati N, Nakata K, Mikoshiba K, Furuhata Y, Sato S, Tei H, Sakaki Y, Kurokawa T, Shiokawa K, Yokoyama KK: Characterization of a novel member of the FGF family, XFGF-20, in Xenopus laevis. Biochem Biophys Res Commun 261: 756-765, 1999
2. Basilico C, Moscalelli D: The FGF family of growth factors and oncogenes. Adv Cancer Res 59: 115-116, 1992
3. Tanaka A, Miyamoto K, Minamino N, Takeda M, Sato B, Matsuo H, Matsumoto K: Cloning and characterization of an androgen-induced growth factor essential for the androgen-dependent growth of the mouse mammary carcinoma cells. Proc Natl Acad Sci USA 89: 8928-8932, 1992
4. Miyamoto M, Naruo K, Seko C, Matsumoto S, Kondo T, Kurokawa T: Molecular cloning of a novel cytokine cDNA encoding the ninth member of the fibroblast growth factor family, which has a unique secretion property. Mol Cell Biol 13: 4251-4259, 1993
5. Emoto H, Tagashira S, Mattei MG, Yamasaki M, Hashimoto G, Katsumata T, Negoros T, Nakatsuka M, Birnbaum D, Coulier F, Itoh N: Structure and expression of human fibroblast growth factor-10. J Biol Chem 272: 23191-23194, 1997
6. Goldfarb M: Functions of fibroblast growth factors in vertebrate development. Cytokine Growth Factor Rev 7: 311-325, 1996
7. Dickson C, Smith R, Brookes S, Peters G: Tumorigenesis by mouse mammary tumor virus: proviral activation of a cellular gene in the common integration region int-2. Cell 37: 529-536, 1984
8. Peters G, Brookes S, Smith R, Placzek M, Dickson C: The mouse homolog of the hst/k/FGF gene is adjacent to int-2 and is activated by proviral insertion in some virally induced mammary tumors. Proc Natl Acad Sci USA 86: 5678-5682, 1989
9. Clausse N, Smith R, Calberg-Bacq CM, Peters G, Dickson C: Mouse mammary tumor virus activates Fgf-3/int-2 less frequently in tumors from virgin than from parous mice. Int J Cancer 55: 157-163, 1993
10. Murakami A, Tanaka H, Matsuzawa A: Association of the hst gene expression with metastatic phenotype in mouse mammary tumors. Cell Growth Diff 1: 1-5, 1990
11. Kapoun AM, Shackleford GM: Preferential activation of Fgf-8 by proviral insertion in mammary tumors of Wnt-1 transgenic mice. Oncogene 14: 2985-2989, 1997
12. Muller WJ, Lee FS, Dickson C, Peters G, Pattengale P, Leder P: The int-2 gene product acts as an epithelial growth factor in transgenic mice. EMBO J 9: 907-913, 1990
13. Kitsberg D, Leder P: Keratinocyte growth factor induces mammary and prostatic hyperplasia and mammary adenocarcinoma in transgenic mice. Oncogene 13: 2507-2515, 1996
14. Penault-Llorca F, Bertucci F, Adelaide J, Parc P, Coulier F, Jacquemier J, Birnbaum D, de Lapeyriere O: Expression of FGF and FGF receptor genes in human breast cancer. Int J Cancer 61: 170-176, 1995
15. Penault-Llorca F, Bertucci F, Sun ZZ, Viens P, Coulier F, Jacquemier J, Birnbaum D: Expression of FGF and FGF receptor genes in breast carcinomas. In: 21st meeting of the International Association for Breast Cancer Research. Paris (France), July 3-5, 1996, Abstract 11, p 34
16. Bansal GS, Yiangou C, Coope RC, Gomm GG, Luqmani YA, Coombes RC, Johnston CL: Expression of fibroblast growth factor 1 is lower in breast cancer than in normal human breast. Br J Cancer 72: 1420-1426, 1995
17. Yiangou C, Gomm JJ, Coope RC, Law M, Luqmani YA, Shousha S, Coombes RC, Johnston, CL: Fibroblast growth factor 2 in breast cancer: occurence and prognostic significance. Br J Cancer 75: 28-33, 1997
18. Bansal GS, Cox HS, Marsh S, Gomm JJ, Yiangou C, Luqmani Y, Coombes RC, Johnston CL: Expression of keratinocyte growth factor and its receptor in human breast cancer. Br J Cancer 75: 1567-1574, 1997
19. Russo J, Barnabas N, Higgy N, Salicioni AM, Wu YL, Russo IH: Molecular basis of human breast epithelial cell transformation. In: Calvo F, Crépin M, Magdalenat H (eds) Breast Cancer Advances in Biology & Therapeutics. John Libbey, Eurotext, Montrouge, 1996, pp 33-43
20. Zhang PL, Chai YL, Ho TY, Calaf G, Russo J: Activation of c-myc, c-neu and int-2 oncogenes in the transformation of the human breast epithelial cell line in MCF-10F treated with chemical carcinogens in vitro. Int J Oncol 6: 963-968, 1995
21. Hajitou A, Calberg-Bacq CM: Fibroblast growth factor-3 is tumorigenic for mouse mammary cells orthotopically implanted in nude mice. Int J Cancer 63: 702-709, 1995
22. Hajitou A, Baramova EN, Bajou K, Noë V, Bruyneel E, Marcel M, Collette J, Foidart J-M, Calberg-Bacq C-M: FGF-3 and FGF-4 elicit distinct oncogenic properties in mouse mammary myoepithelial cells. Oncogene 16: 2059-2071, 1998
23. Soule HD, Vazquez J, Long A, Albert S, Brennan M: A human cell line from a pleural effusion derived from a breast carcinoma. J Natl Cancer Inst 51: 1409-1415, 1973
24. Kern FG, McLeskey SW, Zhang L, Kurebayashi J, Liu Y, Ding IYF, Kharbanda S, Chen D, Miller D, Cullen K, Paik S, Dickson RB: Transfected MCF7 cells as a model for breast cancer progression. Breast Cancer Res Treat 31: 153-165, 1994
25. McLeskey SW, Zhang L, Kharbanda S, Kurebayashi J, Lippman ME, Dickson RB, Kern FG: Fibroblast growth factor overexpressing breast carcinoma cells as models of angiogenesis and metastasis. Breast Cancer Res Treat 39: 103-117, 1996
26. Lehtola L, Partanen J, Sistonen L, Korhonen J, Warri A, Harkonen P, Clarke R, Alitalo K: Analysis of tyrosine kinase mRNAs expressed in MCF7 breast cancer cells. Int J Cancer 50: 598-603, 1992
27. Zhang L, Kharbanda S, Chen D, Bullocks J, Miller DL, Ding IYF, Hantelt J, McLeskey SW, Kern FG: MCF7 breast carcinoma cells overexpressing FGF-1 form vascularized, metastatic tumors in ovariectomized or tamoxifen-treated nude mice. Oncogene 15: 2093-2108, 1997
28. Zhang L, Kharbanda S, Hanfelt J, Kern FG: Both autocrine and paracrine effects of transfected acidic fibroblast growth factor are involved in the estrogen-independent and antiestrogen-resistant growth of MCF7 breast cancer cells. Cancer Res 58: 352-361, 1998
29. Fenig E, Wieder R, Paglin S, Wang H, Persaud R, Haimovitz-Friedman A, Fuks Z, Yahalon J: Basic fibroblast growth factor confers growth inhibition and mitogen-activated protein kinase activation in human breast cancer cells. Clin Cancer Res 3: 135-142, 1997
30. Wang H, Rubin M, Fenig E, DeBlasio A, Mendelsohn J, Yahalom J, Wieder R: Basic fibroblast growth factor causes growth arrest in MCF7 human breast cancer cells while inducing both mitogenic and inhibitory G1 events. Cancer Res 57: 1750-1757, 1997
31. McLeskey SW, Kurebayashi J, Honig SF, Zwiebel J, Lippman ME, Dickson RB, Kern FG: Fibroblast growth factor-4 transfection of MCF-7 cells produces cell lines that are tumorigenic and metastatic in ovariectomized or tamoxifen-treated athymic nude mice. Cancer Res 53: 2168-2177, 1993
32. Kurebayashi D, McLeskey SW, Johnson MD, Lippman ME, Dickson RB, Kern FG: Quantitative demonstration of spontaneous metastasis by MCF-7 human breast cancer cells cotransfected with fibroblast growth factor 4 and LacZ. Cancer Res 53: 2178-2187, 1993
33. Markowitz D, Stephen G, Bank A: Construction and use of a safe and efficient amphotropic packaging cell line. Virology 167: 400-406, 1988
34. Acland P, Dixon M, Peters G, Dickson C: Subcellular fate of the int-2 oncoprotein is determined by choice of initiation codon. Nature (Lond) 343: 662-665, 1990
35. Deroanne CF, Hajitou A, Calberg-Bacq CM, Nusgens BV, Lapiere CM: Angiogenesis by fibroblast growth factor-4 is mediated through an autocrine up-regulation of vascular endothelial growth factor expression. Cancer Res 57: 5590-5597, 1997
36. Noel A, Simon N, Raus J, Foidart JM: Basement membrane components (matrigel) promote the tumorigenicity of human breast adenocarcinoma MCF7 cells and provide an in vivo model to assess the responsiveness of cells to estrogen. Biochem Pharmacol 43: 1263-1267, 1992
37. Gilles C, Thompson EW: The epithelial to mesenchymal transition and metastatic progression in carcinoma. The Breast J 2: 83-96, 1996
38. Butler WB, Berlinski PJ, Hillman RM, Kelsey WH, Toenniges MM: Relation of in vitro properties to tumorigenicity for a series of sublines of the human breast cancer cell line MCF-7. Cancer Res 46: 6339-6348, 1986
39. Basolo F, Venesio T, Calvo S, Fiore L, Fontanini G, Ciardiello F, Toniolo A, Liscia D, Merlo GR: The effects of fgf-3/int-2 on growth and transformation of MCF-10A normal human mammary epithelial cells is distinct from Fgf-1 and Fgf-2. Int J Oncol 4: 1365-1370, 1993
40. Costa M, Danesi R, Agen C, Di Paolo A, Basolo F, Bianchi SD, Tacca MD: MCF-10A cells infected with the int-2 oncogene induce angiogenesis in the chick chorioallantoic membrane and in the rat mesentery. Cancer Res 54: 9-11, 1994
41. Venesio T, Taverna D, Hynes NE, Deed R, Macallan D, Ciardiello F, Valverius EM, Salomon DS, Callahan DR, Merlo G: The int-2 gene product acts as a growth factor and substitutes for basic fibroblast growth factor in promoting the differentiation of a normal mouse mammary epithelial cell line. Cell Growth Diff 3: 63-71, 1992
43. Talarico D, Basilico C: The kFGF/hst oncogene induces transformation through an autocrine mechanism that requires extracellular stimulation of the mitogenic pathway. Mol Cell Biol 11: 1138-1145, 1991
44. Kiefer P, Peters G, Dickson C: The int-2/Fgf-3 oncogene product is secreted and associates with extracellular matrix: implications for cell transformation. Mol Cell Biol 11: 5929-5936, 1991
45. Takei Y, Higashira H, Yamamoto T, Hayashi K: Mitogenic activity toward human breast cancer cell line MCF-7 of two bFGFs purified from sera of breast cancer patients: cooperarive role of cathepsin D. Breast Cancer Res Treat 43: 53-63, 1997
46. Tang CK, Perez C, Grunt T, Waibel C, Cho C, Ruth L: Involvement of heregulin-β2 in the acquisition of the hormone-independent phenotype of breast cancer cells. Cancer Res 56: 3350-3358, 1996
47. McLeskey SW, Zhang L, El-Ashry D, Trock BJ, Lopez CA, Kharbanda S, Tobias CA, Lorant LA, Hannum RS, Dickson RB, Kern FG: Tamoxifen-resistant fibroblast growth factor-transfected MCF7 cells are cross-resistant in vivo to the anti-estrogen ICI 182, 780 and two aromatase inhibitors. Clin Cancer Res 4: 697-711, 1998
48. Noel A, De Pauw-Gillet MC, Purnel LG, Nusgens B, Lapiere CM, Foidart JM: Enhancement of tumorigenicity of human breast adenocarcinoma cells in nude mice by matrigel and fibroblasts. Br J Cancer 68: 909-915, 1993
49. McLeskey SW, Ding IYF, Lippman ME, Kern FG: MDA-MB-134 breast carcinoma cells overexpress fibroblast growth factor receptors and are growth inhibited by FGF ligands. Cancer Res 54: 523-530, 1994
50. Fotsis T, Zhang Y, Pepper MS, Adlercreutz H, Montesano R, Nawroth PP, Schweigerer L: The endogenous oestrogen metabolite 2-methoxyoestradiol inhibits angiogenesis and suppresses tumor growth. Nature 368: 237-239, 1994
51. Klauber N, Parangi S, Flynn E, Hamel B, D'Amato DJ: Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol. Cancer Res 57: 81-86, 1997
52. Folkman J: What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82: 4-6, 1990
53. Jouanneau J, Moens G, Montesano R, Thiery JP: FGF-1 but not FGF-4 secreted by carcinoma cells promotes in vitro and in vivo angiogenesis and rapid tumor proliferation. Growth Factors 12: 37-17, 1995
54. Kim KJ, Li B, Winer J, Armanini M, Gillet N, Philips HS, Ferrara N: Inhibition of vascular endothelial growth factor-induced angiogenesis supresses tumor growth in vivo. Nature 362: 841-844, 1993
55. Relf M, Lejeune S, Scott PAE, Fox S, Smith K, Leek R, Moghaddam A, White House R, Bicknell R, Harris L: Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor β-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res 57: 963-969, 1997
56. McLeskey SW, Tobias CA, Vezza PR, Filie AC, Kern FG, Hanfelt J: Tumor growth of FGF or VEGF transfectcd MCF-7 breast carcinoma cells correlates with density of specific microvessels independent of the transfected angiogenic factor. Am J Pathol 153: 1993-2006, 1998